CCND2 and Miyoshi myopathy: Approximately 20% of MM tumors show elevated levels of cyclin D1 or D3 as the result of chromosomal translocations that juxtapose potent immunoglobulin (Ig) gene enhancers next to CCND1 (11q13) or CCND3 (6p21) [27], and ~7% of MM tumors have Ig translocations involving c-MAF (16q23) or MAFB (20q11), which encode transcription factors that target CCND2 [27,48].